Skip to search formSkip to main contentSkip to account menu

Pretargeted Radioimmunotherapy

A technique used to improve the efficacy of radioimmunotherapy that targets the tumor with both an antibody construct and a radiolabeled hapten prior… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
In recent reports, we have shown that optimized pretargeted radioimmunotherapy (PRIT) based on molecularly engineered antibody… 
Highly Cited
2016
Highly Cited
2016
Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry
The pretargeting system based on the inverse electron demand Diels-Alder reaction (IEDDA) between trans-cyclooctene (TCO) and… 
Highly Cited
2013
Highly Cited
2013
Diels–Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody
Current pretargeting systems use noncovalent biologic interactions, which are prone to immunogenicity. We previously developed a… 
Highly Cited
2012
Highly Cited
2012
Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as… 
Highly Cited
2006
Highly Cited
2006
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group…
PURPOSE No effective therapy is currently available for the management of patients with metastatic medullary thyroid carcinoma… 
Highly Cited
2006
Highly Cited
2006
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Acute myelogenous leukemia (AML) currently kills the majority of afflicted patients despite combination chemotherapy and… 
Highly Cited
2005
Highly Cited
2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
UNLABELLED Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comprised of CC49-(scFv)4 and streptavidin, in… 
Highly Cited
2004
Highly Cited
2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting… 
Highly Cited
2000
Highly Cited
2000
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Pretargeted radioimmunotherapy (PRIT) was investigated in patients with non-Hodgkin's lymphoma (NHL). The PRIT approach used in… 
Highly Cited
2000
Highly Cited
2000
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
UNLABELLED Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidin conjugate, followed by a biotin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)